血栓性血小板减少性紫癜 中国就医指南

Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life-threatening hematologic emergency characterized by microangiopathic hemolytic anemia (MAHA), severe thrombocytopenia, neurologic abnormalities, renal dysfunction, and fever—collectively known as the 'pentad.' It results from systemic formation of platelet-rich microthrombi in small arterioles and capillaries, leading to end-organ ischemia and mechanical red blood cell fragmentation. The primary pathogenesis involves a profound deficiency (<10% normal activity) of ADAMTS13, a metalloprotease responsible for cleaving ultra-large von Willebrand factor (ULVWF) multimers. In acquired autoimmune TTP (the most common form, ~95% of cases), autoantibodies inhibit ADAMTS13 function or accelerate its clearance; in congenital TTP (Upshaw-Schulman syndrome), biallelic mutations in the ADAMTS13 gene cause lifelong enzyme deficiency. Epidemiologically, TTP affects approximately 3–6 new cases per million people annually, with a slight female predominance (F:M ≈ 2:1) and peak incidence in adults aged 30–60 years. Risk factors include female sex, pregnancy/postpartum state, autoimmune disorders (e.g., SLE), certain medications (e.g., ticlopidine, clopidogrel, quinine, interferon-alpha), HIV infection, and stem cell transplantation. Early recognition is critical: untreated mortality exceeds 90%, but prompt plasma exchange (PEX) reduces mortality to <15%. Symptoms often present acutely and nonspecifically—fatigue, pallor, petechiae, purpura, headache, confusion, aphasia, visual disturbances, abdominal pain, and oliguria—and may mimic sepsis, stroke, or ITP. Neurologic manifestations (e.g., fluctuating consciousness, seizures) are particularly characteristic and reflect cerebral microvascular occlusion. Renal involvement is typically mild compared to HUS but may progress to acute kidney injury. Quality of life is significantly impaired during acute episodes due to hospitalization, ICU admission, cognitive sequelae (in up to 30% of survivors), fatigue, anxiety about relapse (10–40% risk over 5 years), and long-term immunosuppressive therapy. Patients frequently experience work disability, social withdrawal, and emotional distress; pediatric and young adult patients face disruptions in education and career development. Chronic management requires vigilant monitoring of ADAMTS13 activity, platelet counts, lactate dehydrogenase (LDH), haptoglobin, and schistocyte burden—even during remission—to detect subclinical relapse early. Psychosocial support, patient education, and multidisciplinary care involving hematologists, nephrologists, neurologists, and mental health specialists are integral to optimizing long-term outcomes.

# 血栓性血小板减少性紫癜（TTP）治疗方案与费用明细（血液科）

一、一线保守治疗（首选，适用于初发/非危重患者）

• •血浆置换（PEX）：每日1次，持续至PLT＞150×10⁹/L且LDH正常，通常5–10次；含血浆输注（新鲜冰冻血浆2000–3000 mL/次）

• •糖皮质激素（泼尼松1–2 mg/kg/d）+ 利妥昔单抗（375 mg/m²，每周1次×4周）

二、二线/难治复发干预（需ADAMTS13检测确认）

• •卡普赛珠单抗（Caplacizumab）：首剂10 mg IV，后续10 mg SC qd，最长30天

• •硼替佐米联合方案（适用于利妥昔单抗无效者）：¥12,000–¥28,000/周期（含药费、监测费）

三、特殊复杂情形处理

• •合并严重器官衰竭或顽固性溶血：转入ICU行连续性肾脏替代治疗（CRRT）支持，费用¥18,000–¥32,000/周
• •造血干细胞移植（极少数遗传性TTP或反复耐药者）：全流程¥350,000–¥520,000（含配型、预处理、移植、抗排异）

方案快速选择指南

• •预算有限/初诊轻症：首选标准PEX+激素，总费用¥12,000–¥22,000
• •中高预算/复发/ADAMTS13抗体阳性：利妥昔单抗+PEX，总费用¥25,000–¥45,000
• •危重/难治/需快速阻断微血管血栓：卡普赛珠单抗联合PEX，医保后自付¥45,000–¥75,000
• •遗传性TTP或多次复发：评估移植可行性，需多学科会诊